Jun 17, 2025
Оfftopic Community
Оfftopic Community
Forums
New posts
Search forums
What's new
Featured content
New posts
New media
New media comments
New resources
New profile posts
Latest activity
Media
New media
New comments
Search media
Resources
Latest reviews
Search resources
Members
Current visitors
New profile posts
Search profile posts
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Install the app
Install
Forums
Information & News
RSS News
Health and Fitness
Anadys Pharmaceuticals Provides Progress Update On Phase II Study Of ANA598 In Hepati
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="tD33NAt" data-source="post: 2080636" data-attributes="member: 124445"><p>Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS) announced that ANA598 dosing has been completed in the first dose cohort, 200 mg bid, in an ongoing Phase II study of ANA598 in combination with pegylated interferon and ribavirin (SOC) in HCV patients. Anadys expects to receive 12-week safety and antiviral response data for the 200 mg bid cohort in the first quarter of 2010. Anadys also announced that all patients have commenced dosing in the second dose cohort, 400 mg bid... <a href="http://feedads.g.doubleclick.net/~a/TZh1KFq2th5d_uIZ0NFGTtoT9w4/0/da" target="_blank"><img src="http://feedads.g.doubleclick.net/~a/TZh1KFq2th5d_uIZ0NFGTtoT9w4/0/di" alt="" class="fr-fic fr-dii fr-draggable " data-size="" style="" /></a></p><p><a href="http://feedads.g.doubleclick.net/~a/TZh1KFq2th5d_uIZ0NFGTtoT9w4/1/da" target="_blank"><img src="http://feedads.g.doubleclick.net/~a/TZh1KFq2th5d_uIZ0NFGTtoT9w4/1/di" alt="" class="fr-fic fr-dii fr-draggable " data-size="" style="" /></a></p><p></p><p><img src="http://feeds.feedburner.com/~r/mnt/healthnews/~4/E4JaQFqAKu4" alt="" class="fr-fic fr-dii fr-draggable " data-size="" style="" /></p><p></p><p><a href="http://feedproxy.google.com/~r/mnt/healthnews/~3/E4JaQFqAKu4/3wHG" target="_blank">More...</a></p></blockquote><p></p>
[QUOTE="tD33NAt, post: 2080636, member: 124445"] Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS) announced that ANA598 dosing has been completed in the first dose cohort, 200 mg bid, in an ongoing Phase II study of ANA598 in combination with pegylated interferon and ribavirin (SOC) in HCV patients. Anadys expects to receive 12-week safety and antiviral response data for the 200 mg bid cohort in the first quarter of 2010. Anadys also announced that all patients have commenced dosing in the second dose cohort, 400 mg bid... [URL="http://feedads.g.doubleclick.net/~a/TZh1KFq2th5d_uIZ0NFGTtoT9w4/0/da"][IMG]http://feedads.g.doubleclick.net/~a/TZh1KFq2th5d_uIZ0NFGTtoT9w4/0/di[/IMG][/URL] [URL="http://feedads.g.doubleclick.net/~a/TZh1KFq2th5d_uIZ0NFGTtoT9w4/1/da"][IMG]http://feedads.g.doubleclick.net/~a/TZh1KFq2th5d_uIZ0NFGTtoT9w4/1/di[/IMG][/URL] [IMG]http://feeds.feedburner.com/~r/mnt/healthnews/~4/E4JaQFqAKu4[/IMG] [url=http://feedproxy.google.com/~r/mnt/healthnews/~3/E4JaQFqAKu4/3wHG]More...[/url] [/QUOTE]
Insert quotes…
Name
Verification
Please enable JavaScript to continue.
Loading…
Post reply
Top